Sirona Biochem (Seite 3093)

[techinvestor69]

Offensichtlich ist die Firma noch lange nicht am Ende.

Guter Aktionärsbrief.

Sirona Biochem Corporation - CEO Letter to Shareholders


VANCOUVER, BC--(Marketwired - July 21, 2014) - Sirona Biochem Corp. (TSX VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) today provided a business update.

Dear Shareholders and Investors,

As announced in our recent news release, I, Howard Verrico, have stepped in as CEO of Sirona Biochem. Although this change is significant, I have always maintained an active role in Sirona's operations throughout its history making this an efficient transition. I can assure you we are moving along on all initiatives as planned. As founder, Chairman of the Board and a major shareholder I will personally ensure the responsibilities and deliverables of CEO are achieved. Under supervision of Sirona's Board, the search, selection and appointment of a new executive management team member will occur as a priority task.

Financial:

In February 2014, we announced the completion of a $1.2M private placement. The original plan was to follow this up with a US led investment of approximately $4 million. This initiative was abandoned since terms did not meet our vision for the direction of our company. The management of the company was and is unwilling to settle for terms that we feel create risk to the current shareholder value.

We anticipate minimal financing needs over the next twelve to eighteen months. To avoid unnecessary dilution, we will continue to apply for government grants and loans where applicable rather than pursue an equity raise. Moreover, we are expecting further substantial milestone payments as well as initial royalty payments.

Our current institutional investors remain very supportive of our future growth strategy. We have recently been encouraged by strong interest from European investors which could bode very well for us going forward. In addition to that, we plan to further increase market awareness for Sirona in the next several months.

Strategy:

Sirona Biochem remains committed to a streamlined business strategy of chemistry, patent and license.

Our expertise remains in creating new chemical compounds (pharmaceutical and cosmetic) that have distinct advantages over existing technologies. Each compound that we create will be licensed to an industry-leading company who will be responsible for developing, manufacturing and selling the compound. In return, Sirona will receive licensing fees, milestone payments and ongoing royalty payments.

Through our platform technology, we have been able to diversify our risk across multiple projects, increase our portfolio size more quickly and continue to build our credibility and reputation as experts in the discovery of innovative therapeutics.

The Board of Directors is taking an increasingly active role in refining the company strategy and how it is implemented. Our Board has a diverse and valuable skill set which we are utilizing to the fullest extent.

Operations:

In March, we bolstered our France team with the addition of Claude Nivet. Claude's official title is Laboratory Manager. This role was developed specifically to assist in growing operations and relieving our Chief Scientific Officer, Geraldine Deliencourt-Godefroy, of some of her non-scientific tasks. This will allow her to focus on innovation and management of the current pipeline.

Our current R&D focus is on the following:

Assist Obagi/Valeant in the manufacturing and monetization of our skin lightener. Obagi/Valeant will be responsible for the formulation and sales of the compound;
Develop the anti-aging library of compounds in anticipation of government funding and commencement of pre-clinical studies;
Synthesize the anti-inflammatory compound for our Bloom Burton partnership.

As projects progress and resources become available, we will explore new areas where our technology will add significant value.

Current Business Development:

At the end of April 2014, Wanbang Biopharmaceuticals began pre-clinical validation for Sirona Biochem's second generation SGLT2 Inhibitor. To date, Sirona has received Wanbang's initial licensing fee and the Chinese government's innovation tax application has been approved. Wanbang has successfully hired an expert in pharmacology and toxicity to lead the project and compound synthesis has begun to ensure quantities of the compound will be available for all future clinical trials. Further updates from Wanbang will become available shortly.
Obagi Medical Products is moving forward on Sirona Biochem's skin lightening compound TFC-849. Obagi Medical Products is responsible for all development, manufacturing and sales of the compound and in return Sirona Biochem will receive licensing and milestone fees and ongoing royalty payments.
Our Joint Venture with Bloom Burton and Co. is progressing nicely. Once the first compound is synthesized, it will enter early stage testing. Bloom Burton is Canada's largest and most active healthcare-specialized investment banking firm. The goal of this joint venture is to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Sirona's Chief Scientific Officer recently attended industry meetings in New York City. The meetings were very successful and have generated multiple potential partnerships. We will provide updates regarding these opportunities on the next shareholder letter. Although we have a number of significant partnering initiatives fully executed and underway, we are continuing to explore new partnership opportunities and currently have multiple ongoing conversations with large Pharma and cosmetic companies around the world.

Our goal has always been for Sirona Biochem to become the global leader in the process of compound stabilization which leads to unlimited applications in pharmaceuticals and cosmetics. The value of Sirona Biochem lies in its technology and we intend to put our resources behind this. At the end of the day, our common goal is to create shareholder value which is exactly what we work to accomplish every single day. Sirona is well positioned to take advantage of some of the major opportunities that are available to us and we are working diligently to take our company to the next level.

I sincerely appreciate the past support of our shareholders and ask for your future support as we move forward.

Best Regards,

Dr. Howard Verrico
CEO, Chairman of the Board
Sirona Biochem

About Sirona Biochem Corp.

Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information please visit www.sironabiochem.com.

For more information regarding this press release, contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: [phone]
Email: [e-mail]

[manffreddoo]

Antwort auf Beitrag Nr.: 47.227.238 von techinvestor69 am 28.06.14 20:27:53

Quo vadis?
....den Bach runter ins grosse Meer........
M.

[techinvestor69]

CEO zurückgetreten und er verkauft jetzt auch seine paar Aktien.

Quo vadis?

[techinvestor69]

3.6.2014

SIRONA BIOCHEM ANNOUNCES WANBANG BIOPHARMACEUTICAL'S LAUNCH OF PRE-CLINICAL VALIDATION

Sirona Biochem Corp. licensee Wanbang Biopharmaceuticals has begun preclinical validation for Sirona Biochem's second-generation SGLT2 inhibitor. To date, Sirona has received Wanbang's licensing fee, the Chinese government's innovation tax application has been approved, Wanbang has successfully hired an expert in pharmacology and toxicity to lead the project, and compound synthesis has begun to ensure quantities of the compound will be available for all future clinical trials.

About the licence agreement with Wanbang Biopharmaceuticals

Wanbang Biopharmaceuticals secured the exclusive rights to sell Sirona Biochem's SGLT2 inhibitor in the People's Republic of China for $9.5-million (U.S.) in upfront and milestone payments with continuing royalty payments as a percentage of all sales. Wanbang is responsible for financing and managing all clinical validation for the diabetes drug, removing the financial and resource burden for the development of the second-generation SGLT2 inhibitor from Sirona Biochem. Sirona Biochem will oversee and contribute to the design and execution of all clinical studies and will receive all data generated by Wanbang. Following the successful completion of each study, Sirona will receive a milestone payment from Wanbang and the global value of Sirona's SGLT2 inhibitor will rise significantly. Sirona has the option of licensing its SGLT2 inhibitor to the rest of the world at any time; previous transaction values for the first generation of SGLT2 inhibitors globally include:

Empagliflozin, one of a two-compound licensing deal between Boehringer Ingelheim and Eli Lilly for a one-time payment of 300 million euros and milestone payments of 625 million euros;
Dapagliflozin (Forxiga), one of a two-compound licensing deal between Bristol Myers Squibb and AstraZeneca for an upfront payment of $100-million (U.S.) and milestone payments of up to $1.25-billion (U.S.);
Bristol Myers Squibb and AstraZeneca expand licensing deal of Dapagliflozin to include Japan; deal estimated to bring more than $1-billion (U.S.).

About Wanbang Biopharmaceuticals

Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes. Wanbang Pharma is a subsidiary of Fosun Pharmaceutical Group, which is listed on the Shanghai Stock Exchange. Fosun Pharma, one of the major shareholders of Sino Pharma, the largest drug distributor in China, is part of the Fosun group, the leading non-state-owned enterprise group in China, which is listed on the Hong Kong Stock Exchange.

[techinvestor69]

29.5.2014

SIRONA BIOCHEM EXPANDS EXCLUSIVE SKIN LIGHTENING LICENSE WITH VALEANT PHARMACEUTICALS TO INCLUDE AMBI AND KINERASE

Sirona Biochem Corp. has expanded its exclusive licence with Valeant Pharmaceuticals for Sirona's skin-lightening compound TFC-849 to include AMBI and Kinerase. Under the terms of the licensing agreement, Valeant has the exclusive global rights to TFC-849 for use throughout its international portfolio of companies and brands. AMBI and Kinerase, along with Obagi Medical Products (see press release dated Jan. 29, 2014), are part of Valeant's diverse portfolio focused primarily on dermatology.

"We are excited to add AMBI and Kinerase, two of Valeant Pharmaceutical's premium skin care companies, to the commercial licence for TFC-849," commented Neil Belenkie, chief executive officer of Sirona Biochem. "Adding premium brands with global distribution through over-the-counter store sales and significant e-commerce platforms ensures that our compound will reach leading skin-lightening and brightening markets around the world."

The global skin-lightening market is projected to reach approximately $20-billion by 2018, representing one of the fastest-growing segments within the global beauty industry. Sirona has created and patented a skin-lightening active ingredient which is up to 14 times more effective than Arbutin, one of the world's leading skin-lightening compounds. Most importantly, Sirona's compound is 100 per cent safe and can be sold everywhere in the world.

[techinvestor69]

20.5.2014

SIRONA BIOCHEM'S ANTI-AGING GLYCOPROTEIN SUCCESSFULLY EXTENDS CELL LIFE IN SERUM DEPRIVATION STUDY

Sirona Biochem Corp.'s anti-aging compound TFC-837 was proven to extend cell life with outstanding results in a 12-day serum-deprivation study. The study subjected unprotected and glycoprotein-protected fibroblast cells to a serum-deprived environment for a period of 12 days. By day 10 of the study, 100 per cent of the unprotected cells were dead. In contrast, 75 per cent of the glycoprotein-protected cells continued to be fully viable at the conclusion of the 12-day study.

"We couldn't be more excited by these results and the potential value these compounds can create," commented Neil Belenkie, chief executive officer of Sirona Biochem. "Results such as these are the reason we have attracted globally respected partners for this project, including Jean-Michel Cousteau, Fabien Cousteau and the Cincinnati Children's Hospital Medical Center. This is absolutely groundbreaking technology; the first in a new family of synthetic glycoproteins successfully created and patented by our scientific team."

Next steps for the development of this compound include additional studies to validate other cell preservation qualities and the standard cohort of cosmetic safety studies necessary for launch of this compound as an anti-aging ingredient. The goal for this compound is to be available for acquisition by a global partner within six months. Desired terms for an exclusive licence will be the same as the terms secured in the global exclusive licence with Obagi Medical Products (subsidiary of Valeant Pharmaceuticals); licensing fee, milestone fee and a continuing royalty payment structure with minimum sales revenue requirements.

Targeted applications for this new family of compounds

Early data support targeted applications including the following:

Cosmetic (no Food and Drug Administration approval required, inexpensive studies, quick to market):
Anti-aging cream (global marketplace, $300-billion in annual sales).
Pharmaceutical:
Extend platelet storage beyond current four- to five-day limitation;
Improve outcomes for beta-islet cell transplants;
Improve stem cell storage solution versus conventional mediums;
Improve organ transplantation donor-to-recipient windows;
Protect against harmful UV or radiation.

Project background

In 1969, an antifreeze glycoprotein was discovered in fish living under the Antarctic icecaps. The discovery was groundbreaking because this specific glycoprotein enabled the Antarctic fish to survive (and not freeze solid) in the subzero temperatures. Sirona Biochem's subsidiary, TFChem (France), has synthesized and stabilized its derivative of this antifreeze glycoprotein for human use; in the process greatly expanding the protective abilities of the original antifreeze glycoprotein. While the natural glycoprotein only protects cells from low temperatures, Sirona Biochem's patented family of glycoproteins is being tested in multiple cells types to protect against additional stressed environments including oxidative stress, UV rays, cold temperatures and nutrient deprivation.

[techinvestor69]

zu tief ins Weinglas geschaut?

[manffreddoo]

Hi.......
kaum mehr Lebenszeichen,geschweige denn Rauchzeichen..........
...aber,wenn die Nacht am tiefsten ist der Tag am nächsten........
Jon,leg Brennstoff nach............
M.

[manffreddoo]

...........hi......
noch jemand dabei..........
ist recht preiswert geworden.....wenn es denn mal wieder aufwärts geht......
vielleicht gibt es irgendwann doch noch eine positive,den Wert beflügelnde Meldung aus dem Unternehmen.
P.S. :Meine Prognose zu Santhera(Kurs steigt dreistellig am 2.4. ist Realität geworden.Das war Glück.Mal sehen ob es mit SQI DIAGNOSTIC, meinem neuen Biotechwert auch so kommt. Chancen stehen günstig,Kurs hier noch unten und Interesse der Biobranche an deren Technologie ansteigend........Aber....DYOR.
M.
M.

[manffreddoo]

Hi Jon
welche chance gibst du diesem Wert noch?
Es gibt einfache keine positiven News.
Werde eher nicht niedrig wieder einsteigen......Schau dir mal Santhera an....pirscht sich an sein Jahreshoch ran....bei Zulassung von Raxone wird der Kurs möglicherweise dreistellig steigen.......mal Anteo D. angeschaut?
Meiner Meinung wieder günstige KK...........und Geoff hat noch einige Poker im Ärmel(Kooperationen mit Big Pharma)
Grüsse
M.